Spectral to unveil its stand-alone pump ahead of 510K submission Toronto, Ontario, February 12, 2015 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) (OTC QX: EDTXF) a Phase III company developing the first therapy for patients with septic shock guided by a diagnostic, today announced that it will present at the upcoming 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) conference in San Diego, California on February 18, 2015 during an interactive luncheon session.

The session will focus on the topic of endotoxin removal using the Toraymyxin™ column (‘PMX”), an update on the EUPHRATES trial and a presentation of up-to-date evidence on the effectiveness of PMX collected from European clinical trials, medical registries and a Japanese national database.

Spectral will also unveil, during an invitation only session, its proprietary hemoperfusion/RRT (renal replacement therapies) machine, which is specifically designed to simplify its treatment for patients with septic shock. The machine is intended for use in acute care settings under the direction of doctors and nurses. The Company expects to secure CE mark, FDA 510K licensing and clearances in the current fiscal year in preparation for the potential commercial launch of its septic shock treatment device, PMX, in 2016.

Click here to view the full news release.